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ABSTRACT
Diabetic retinopathy (DR) is a complication which occurs due to diabetes mellitus leading to loss of vision and hindering the quality of patient life by 
damaging the layer of retina at the posterior segment of the eye. According to the survey around 285 million peoples are suffering from visual loss 
out of these 65% of people are more than 50 years old and 82% of blind patients are more than 50 years old. The diseases that occur in the posterior 
segment of the eye like, cytomegalovirus retinitis, posterior uveitis, age related macular degeneration and diabetic retinopathy needs a novel delivery 
system that can improve the concentration of drugs that reaches posterior segment of the eye. The development of new drug delivery system gained 
more importance in the field of research in which nanotechnology is the most considered approach. The nanotechnology-based systems such as 
nanoparticles, nanoliposomes, niosomes, nanomicelles, nanoemulsions, nanogels, cyclodextrins, dendrimers, and quantum dots are developed as a 
new formulation for drug delivery. The rationale behind the nanoparticle systems is its ability to formulate a sustained, controlled release dosage form, 
painless, safe, non-invasive system to overcome the major barriers in the treatment of DR. Based on the nanoparticles, some approaches are exploited 
for more effective conveyance of drug toward the posterior segment. Thus, these advanced delivery systems progress the therapeutic efficacy of the 
drug and patient’s obedience and life quality. In this review, the new therapeutic treatments and their managements were discussed and methods of 
drug delivery to reach the posterior segment of eye.
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INTRODUCTION
Diabetic retinopathy (DR) arises in people having diabetes for 
prolonged period, and it causes vision loss. It affects the retina by 
damaging the layer, and at the back of the eye, light-sensitive lining 
appears. In the retina, minute blood vessels leak blood, extrafluids, 
and tissues present in the retina swells, results in gloomy or blurred 
vision and if untreated leads to vision loss (Fig. 1) [1]. The diseases 
such as glaucoma, age-related macular degeneration, and DR affect the 
posterior segment of the eye and if not treated in time cause permanent 
vision loss. The therapeutic agents that affect the posterior segment 
are administered through intravitreally [2,3]. The administered drug 
shows short half-life and less tissue permeation with chronicity of 
diseases, maintain visual acuity, frequent drug administration, and to 
avoid disease progression [4]. For the researchers, significant challenge 
remains in maintaining and assuring the therapeutic dosage of the 
drug in the target tissue and drug delivery approaches specifically to 
the back of the eye. There are many advanced biomedical applications 
in nanotechnology-based treatment for DR such as gene therapy, novel 
drug discovery techniques, and drug delivery [5]. Several advantages 
of nanoparticle relatively to drug administration alone or to classic 
drug delivery systems such as (1) delivery of drugs to specific cells and 
tissues, (2) sustained drug delivery, and (3) reduced side effects are 
present. In the pathophysiology of DR, increased level of adenosine in 
the retina is seen. The selective adenosine receptor antagonist inhibits 




NPDR is the preliminary stage, in which symptoms occurring will be 
mild or not existed and blood vessels are weakened in the retina. In 
blood vessels, the minute bulges called microaneurysms appear in 
blood vessels, this causes leakage of fluids in the retina and it leads to 
swelling of the macula.
Proliferative DR (PDR)
PDR is the advanced form of the disease. In this phase, oxygen in retina 
is deprived due to circulation problem, thus resulting in development of 
new fragile blood vessels in the vitreous and in the retina, at the back of 
the eye. Gel-like fluids fills into the vitreous; the new blood vessels leak 
blood and form blurred or cloudy vision (Fig. 2).
PDR
The people suffering from diabetes are affected by PDR which is very 
common disease and causes vision loss. The abnormal growth of 
blood vessels in the retina called neovascularization occurs along with 
bleeding and formation of the fibrous tissue. The foremost contribution 
for DR includes production of more vascular endothelial growth factor 
(VEGF); new blood vessel is induced by growth factor and rises the 
permeability of the existing blood vessels [9]. In some cases of severe 
NPDR and PDR, panretinal laser photocoagulation is the backbone for 
treatment in DR. About 50% of the vitreous hemorrhage and risk of DR 
is reduced and in 12 months, about 50% of severe visual loss is reduced 
by giving the treatment by panretinal laser photocoagulation [10]. The 
use of anti-VEGF treatment for PDR affects individuals like vitrectomy 
intended for vitreous hemorrhage, for diabetic macular edema (DME), 
and for anterior segment neovascularization and as substitute for 
panretinal laser photocoagulation for PDR similarly present [11]. After 
2 years of treatment with intravitreal ranibizumab, an anti-VEGF agent 
is demonstrated to improve the visual acuity in people as compared 
through panretinal laser photocoagulation treatment [12]. For the 
treatment of the last-stage complication of vitreous hemorrhage and 
retinal detachment, the vitreoretinal surgery is used (Fig. 3).
DME
DME remains as the main reason for diabetes correlated to loss of 
vision [13,14]. In macula of the retina, the accretion of extravasated 
lipids and proteins occurs and breakdown of tight blood–retinal 
barrier is seen. The DME can be treated by intravitreal injections of 
anti-VEGF agents, corticosteroids, and laser photocoagulation. The aim 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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of this therapy is to improve and maintain the visual acuity [15,16]. 
The anti-VEGF shows the better visual acuity when compared to 
laser photocoagulation [17]. For inhibiting the inflammation and 
reducing capillary permeability, patients of DME are treated with 
corticosteroids [18]. Recent studies suggested that intravitreal 
triamcinolone acetonide or microimplants loaded with corticosteroids 
like dexamethasone has shown significant improvement in visual acuity 
for DME when used over 3 years [19,20].
Mechanism of DR
Diabetes can be characterized by means of resistance to insulin, 
hyperglycemia, absolute or relative lack of insulin action, and growth 
of diabetes detailed pathology in the retina [22]. The elementary 
trade of the disease comprises of loss of pericytes, neovascularization, 
thickening of the basement membrane, microaneurysms, and 
breakdown of blood–retinal barrier [23] (Fig. 4).
Polyol pathway
The polyol pathway can be explained by a number of mechanisms 
such as osmotic pressure induced by sorbitol, decrease in ATPase 
activity, increase in cytosolic NADH/NAD+, and decrease in cytosolic 
nicotinamide adenine dinucleotide phosphate (NADPH). It is a metabolic 
pathway which consists of two steps, first, the glucose is reduced to 
sorbitol and second, the sorbitol converted to fructose (Fig. 5) [25]. 
The rate-limiting enzyme in the polyol pathway is aldose reductase 
enzyme. The cofactor called NADPH reduces glucose to sorbitol with 
the help of aldose reductase enzyme and the cofactor called NAD+ 
metabolize sorbitol to fructose using sorbitol dehydrogenase. Sorbitol 
dehydrogenase has a low capacity and high affinity toward sorbitol and 
aldose reductase has low affinity and high capacity toward glucose.
Protein kinase C (PKC) pathway
In this pathway, the family of multifunctional serine/threonine kinase 
is present which are involved in protein control. In patients with 
diabetes microvascular modification rises from hyperglycemia-induced 
activation of PKC. In this family, 12 PKC isoforms are identified and are 
subdivided into 3 groups: Atypical, classical, and novel [26]. There are 
several isoforms that functions in a different biological system. The 
activation of PKC also occurs in plasma membrane when the messenger 
isoforms binds to the regulator domain. Diacylglycerol (DAG) enhances 
the classical isoforms such as PKC-α, -β1/2, and PKC-δ. Nine isoforms 
are activated by DAG, a lipid messenger and alteration of DAG-PKC 
pathway are the important role in diabetic diseases. PKC-b plays an 
important role in signaling component for endothelial cell permeability 
and VEGF. Several isoforms which are involved in PKC activation are 
responsible for pathogenesis for DR [27].
Hexosamine pathway
In retinal tissues of rats and humans, the hexosamine content is more 
with diabetes. The glucose flux has been increased in in vitro and 
in vivo studies through hexosamine pathway have been concerned in 
diabetic vascular problems, insulin resistance, and synthesis of growth 
factor stimulates [28]. In this pathway the conversion of fructose- 6- 
phosphate to glucosamine- 6- phosphate, an essential precursor for 
glycosylation of lipids and proteins by glutamine fructose- 6- phosphate 
amido-transferase (GFAT) a rate limiting enzyme [29]. The transcription 
of TGF-b1 and plasminogen activator inhibitor-1 increases when 
conversion of glucose to GFAT blocks hyperglycemia-induced which 
inhibits the rate-limiting enzyme. Hexosamine pathway which is 
activated by hyperglycemia results in many alterations of protein level 
and gene, which are contributed to the pathogenesis of DR [30].
Fig. 1: Normal retina vs. diabetic retinopathy [7]
Fig. 2: Schematic representation of classification of diabetic 
retinopathy [8]
Fig. 3: Schematic illustration of diabetic retinopathy comprises 
of diabetic macular edema and proliferative diabetic 
retinopathy [21] 
Fig. 4: Schematic illustration of mechanisms complexed in 
diabetic retinopathy [24]
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Advanced glycation end-product (AGE) formation
The accumulation of advanced glycation end products occurs when the 
retina is more exposed to hyperglycemia and it leads to DR. AGEs are lipids 
and proteins which are oxidized and non-enzymatically glycated after 
it is exposed to aldose sugars. In humans, the chemically characterized 
AGEs are present such as carboxymethyl lysine, carboxyethyl lysine, and 
pentosidine. These chemically characterized AGEs help in the formation 
of AGEs in hyperglycemic patients. The Schiff bases and Amadori products 
are formed by the process of glycation and oxidation [31].
Current treatments for DR
Treatment for hyperglycemia and hypertension are suggested for 
averting or striking development of DR, previously for the treatment 
of laser photocoagulation, anti-VEGF agents, or intravitreal injections 
of corticosteroids and vitreoretinal surgery are executed. Therefore, 
new treatments are required for the early stages of DR [32,33]. The 
laser photocoagulation directly treats to the leaky blood vessels by 
photocoagulation or by removing newly formed blood vessels in the 
retina. The peripheral retina of eye the is involved in the formation of 
VEGF responsible for neovascularization. The animal studies of reduced 
hypoxia and improved retinal function in mice are supported recently 
to this concept with degenerated or chemically ablated photoreceptors 
and anti-angiogenic therapy was used to improve the vision in patients 
through DME and PDR [34,35].
Treating the classical risk factor
In type 2 diabetic patients population of UK Prospective Diabetes 
Study, 39% of reduction is seen in the risk of laser photocoagulation 
was associated with intensive versus conventional management [36]. In 
type 1 diabetic population of diabetes regulator and complication trials, 
the risk of new retinopathy was reduced about 76% and progression of 
existing retinopathy of about 54% by tight against less tight glycemic 
control by means of insulin [37]. Serum lipids have a reduced amount 
of impacting the development of DME or PDR [38]. For preventing or 
arresting DR, the tight control of the blood pressure is important, this 
results in ADVANCE and ACCORD Eye proved ambiguous for DR with 
managing blood pressure in clinical trials [39]. Recent studies show 
that, there is also a development of DR with control of glucose level in 
blood and without hypertension. For PDR, the heritability evaluation 
ranging from 25% to 50% [40,41].
Anti-VEGF in DR
VEGF stands as a homodimeric protein in the range of 35–45 kDa, which 
exist in several isoforms. The production of vascular permeability 
factor and endothelial cell-specific angiogenic factors are increased 
by hypoxia. In recent studies, monoclonal antibodies which are 
administered through intravitreal injection for treating ocular diseases 
because these neutralizes the VEGFs. In DR, VEGFs are more expressed 
due to hypoxia and the capability to rise the penetrability of the blood–
tissue barriers which occur in retinal cells are main stimulation for the 
growth of retinal neovascularization [42]. The drugs which are used as 
anti-VEGF are bevacizumab, ranibizumab, and pegaptanib.
Bevacizumab
It is a recombinant humanized antibody which shows activity in 
isoforms of VEGF-A. For DR, iris neovascularization, and DME, the 
bevacizumab, a monoclonal antibody, is vera y effective treatment [43]. 
The stability of monoclonal antibodies at the stage of production, 
drug release, and in vivo performances are limited when these drugs 
are loaded into nanoparticles. Polymeric nanoparticles are very useful 
system for ophthalmic drug delivery because of its biocompatibility, 
non-toxicity, and diversity [44].
Ranibizumab
In the treatment of DME, the ranibizumab is effective when it is 
administered through intravitreal injection. These drugs rapidly 
improve the vision and further vision loss is reduced and non-
ocular side effects [45]. The combination of intravitreal injection 
of ranibizumab and panretinal photocoagulation shows effective 
treatment for PDR [46]. The hypertension and renal side effects that 
include glomerular thrombotic microangiopathy and proteinuria 
are caused when chronic anti-VEGF therapy is given [47]. The use of 
ranibizumab in the treatment of DME over 5-year period was not 
related with ocular or systemic effects [48].
Pegaptanib
It is an aptamer which binds to the isoforms of VEGF-A. In patients with 
DR, the intravitreal pegaptanib shows regression of neovascularization on 
retinal neovascularization [49]. In patients having DME, this drug blocks 
165 amino acid isoforms of VEGF, this results in improved visual acuity, 
thickness of central retina is reduced and reduction in the supplementary 
therapy with photocoagulation associated with sham injection [50].
Corticosteroids
These are the class of drugs which has more anti-inflammatory activity. 
It reduces the vascular permeability and reduces the breakdown of 
blood–retinal barrier and it also reduces the VEGF expression [51]. 
Various corticosteroids that are used in the DR are triamcinolone 
acetonide, dexamethasone, and fluocinolone acetonide.
Triamcinolone acetonide
In management of DR, the common corticosteroid is triamcinolone 
acetonide delivered by intravitreal route and it is more suitable 
approach for delivery of drug to the posterior segment [52]. In posterior 
segment, the intraocular concentration is achieved by triamcinolone 
acetonide. Around 56% of patients have improved their visual acuity 
by intravitreal triamcinolone acetonide when compared with 26% of 
patients with placebo [53].
Dexamethasone
It is the well-known corticosteroids which has a high anti-inflammatory 
effect used in the treatment of chronic and acute eye disease [54]. The 
dose of the dexamethasone is instillation of 0.1% 3–4 times per day. If 
the dose extended for more than 4 times a day, it causes glaucoma and 
damage to optic nerve and also effects on visual acuity and posterior 
sub- capsular cataract development and cornea become thin [55].
Fig. 5: Schematic illustration of polyol pathway and aldose 
reductase [22]
57
Asian J Pharm Clin Res, Vol 11, Issue 11, 2018, 54-61
 Jyothi and Gupta 
Fluocinolone acetonide
It is the potent corticosteroid which is used in the treatment of eye 
diseases and it is applicable in the treatment of DME [56]. In patients 
with DME, clinical trials indicate the significant reduction in ocular 
edema [57].
Antioxidants
The pathogenesis of several diseases such as hypertension, DR, and 
ischemic cardiovascular diseases caused due to imbalance between the 
antioxidants mechanism and reactive oxygen species (ROS) [58,59]. 
In diabetic patient’s, retinal inflammation are caused due to increase 
in oxidative stress [60]. The inflammatory responses are mediated by 
ROS through modifying the inflammatory genes expression. In retina, 
the concentration of polyunsaturated fatty acids is high and oxygen 
demand is also high. In human, the retina consumes 300–600% of 
oxygen as compared with the cerebral cortex and cardiac muscle [61]. 
There are several ROS generated are free-radical superoxide, peroxyl, 
hydroxyl and hydroperoxyl, and non-radical hydrogen peroxide [62] 
(Table 1).
Route of administration to eye for DR
The route of administration is selected based on the target site of action 
and on convenience. There are some of the routes which are predicted 
for ocular delivery includes topical, systemic, intravitreal, and in recent 
studies, based on periocular routes are used. For anterior segments, 
topical route is preferred, and for the posterior segment, both periocular 
and intravitreal routes have been used [73].
Topical route
It is the most frequently used route which is more convenient route 
for the patients. This route has a major limitation for anterior segment 
such as bioavailability of the drug is low, limited contact time, and 
transcorneal permeation is low [74]. Recent studies have discovered 
that a small molecule of nepafenac formulated as topical drops for 
treating initial stages of retinopathy to retina. The study describes 
the inhibition of abnormalities in DR within 2 months of nepafenac 
as a topical drop in diabetic rats [75]. In other study, the topical drop 
instillation of ranibizumab reaches the retina adequately through 
transscleral route. The low concentration of ranibizumab can able to 
prevent VEGF in vitreous, frequency of administration is high, cost is 
high [76].
Intravitreal route
For intraocular administration of non-anti-VEGF and anti-VEGF 
therapeutics, the intravitreal route is maintained as the best route. 
The application of this route includes, avoidance of blood–ocular 
barrier to attain higher drug concentration in vitreous and it also 
avoid adverse effects resulting from systemic administration. The 
drugs which are present in the vitreous are rapidly cleared therefore 
repeated administration are necessary to maintain effective therapy, 
but there is an adverse effect for repeated administration [77]. The 
anti-VEGF injections causes economic problem on both patient and 
health services, and this can be reduced if studies support the use of 
low-priced and easier-to-administer injections.
Periocular
The periocular offers a good option for drug delivery to the retina or 
vitreous humor. The administration of drug from periocular route 
is done through peribulbar, subconjunctival, posterior juxta-sclera, 
subtenon, and retrobulbar spaces [78]. The periocular route is relatively 
a longer route and it has to cross the barriers such as sclera, Bruch’s 
membrane, episclera, and choroid to reach the retina or vitreous 
humor. Subtenon triamcinolone acetonide shows high level in vitreous 
humor of retinopathic patients than with idiopathic molecular hole 
patients, rhematogenous retinal detachment, and macular epithelial 
membrane [79]. Novel drug delivery system can sustain or improve the 
periocular therapeutics. Considering these studies, periocular route 
has more adopted route for delivering drugs to retinopathic patients 
than compared to intravitreal injections.
Non-invasive ocular drug delivery system
The eye is a delicate sensory organ that is comparatively isolated from 
systemic access by blood–retinal, blood–vitreous barriers, and blood–
aqueous; as a result, the eye exhibits some unusual pharmacokinetic and 
pharmacodynamic properties [80]. New technologies for ophthalmic 
drug delivery have received much attention over the past few years 
such as microspheres, prodrugs, nanotechnology, polymeric gels, 
liposomes, and inserts. These vehicles have been designed to increase 
the amount of drug that can penetrate the cornea by minimizing 
physiological factors such as drainage, blinking, and tearing. The 
two main approaches in improving the ocular bioavailability are 
by prolonging the contact time on ocular surface and increasing the 
corneal permeability.
Nanotechnology applied to ocular delivery
Nanoparticles
Nanoparticles are nanometer-sized particles in the range of 0.1–
100 nm. In medical purposes, nanoparticles have potential application 
such asgene therapy, drug delivery, and imaging [5]. Nanoparticles 
can afford various advantages as a drug delivery system such as (1) 
sustained delivery, (2) delivery of drug to the specific sites or tissues, 
(3) water-insoluble drugs are delivered and large biomolecular drugs 
are improved, and (4) toxicological reactions and side effects are 
reduced [81]. In ocular diseases, the nanoparticles bypass the biological 
barriers such as blood–retinal barriers and blood–brain barriers 
included in the blood–neural barriers. In the biological system, the 
determinants for therapeutic effects are physicochemical properties 
such as surface charge, shape, and size. The size of nanoparticles in 
the range of 2 and 100 nm are suitable for systemic administration 
and for the therapeutic purposes. Smaller nanoparticles in the range of 
<5 nm is susceptible for clearance from the targeted tissues and renal 
excretion [82]. Gold nanoparticles in the range of 20 nm are suitable 
Table 1: Antioxidants used in the treatment of diabetic retinopathy
Antioxidants Mechanism Formulation References




α‑tocopherol It prevents lipid peroxidation Nanoemulsion [65]
Resveratrol It reduces the oxidative stress in retina







α‑lipoic acid Oxidative stress in retina is reduced





Curcumin It reduces the oxidative stress in retina





SLN: Solid–lipid nanoparticles, NLC: Nanostructured lipid carriers, VEGF: Vascular endothelial growth factor 
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for bypassing through blood–retinal barrier and gold nanoparticles 
are in the range of 100 nm were not detected in retinal layers when 
administered the drugs intravenously [83].
Nanoliposomes
Nanoliposomes are single or multiple bilayer lepidic membrane 
surrounded by an aqueous core or compartment. These are artificial 
vesicles formed from synthetic or natural cholesterol and non-toxic 
phospholipids. The properties of the liposomes are depending on 
the lipid composition, size, surface charge, fluidity of bilayers, and 
preparation method [84]. The liposomes are suitable for delivery 
of therapeutics dual times due to non-covalent encapsulation of 
lipophobic drugs which are present in core and hydrophobic drugs 
which are present in bilayers. A cholesterol-poly(ethylene) glycol 
formulation was used to the delivery of sirolimus, a lipophilic 
multitherapeutic agent, whose poor water solubility is a barrier to 
effective topical delivery [85]. Particle size was very small, compared to 
liposomal preparations containing cholesterol, and size was uniformly 
distributed. Further applications on eye cell-based treatments can take 
benefit of this non-viral gene delivery Nanosystem vector. Nevertheless, 
it is known that in vivo drug release from nanoliposomes may be 
affected by environmental conditions making this phenomenon quite 
complex and, somehow, not stable nor effective [86]. Recently, there 
are 11 liposomal formulations accepted for medical use, being several 
under clinical and preclinical development [87].
Niosomes
Niosomes are lamellar (bilayer) structures, similar to liposomes, 
composed of non-ionic surfactant molecules surrounding an aqueous 
compartment [88]. In ocular delivery, lamellar structures are favored 
over vesicular system because chemically they are stable; raw materials 
are easily available and less expensive; unlike phospholipids, does not 
require any conditions and precautions for handling of surfactants, 
which make them more attractive for industrial manufacturing; they 
are biocompatible, biodegradable, and non-immunogenic [89].
Nanomicelles
Nanomicelles contains amphiphilic molecules, in aqueous media, 
they are self-assembled to form organized structure where the polar 
head groups are in connection with the surrounding solvent, and the 
hydrophobic single-tail regions are oriented toward the nanomicelle 
center. The self-assembly occurs at concentrations greater than the 
critical micelle concentration [4]. Nanomicelles are similar to liposomes, 
whereas liposomes are composed of lipid bilayers and nanomicelles 
are made of monolayers [90]. In ocular drug delivery, nanomicelles 
offer unique advantages due to their nanoscale size and permeation 
over ocular epithelia is increased with no irritation. Nanomicelles 
can be formed with either: (1) Surfactants like anionic surfactants 
(e.g., sodium dodecyl sulfate), non-ionic surfactants (e.g., n-dodecyl 
tetraethylenemonoether), and cationic surfactant (e.g., dodecyl 
trimethylammonium bromide) or (2) polymeric systems [91]. The 
sustained dexamethasone delivery from nanomicelles for in vitro 
transscleral iontophoresis was investigated using a mixed micellar 
solution constituted by mixed and simple micelles prepared with 
addition of sodium taurocholate alone along with egg lecithin [92]. The 
nanomicelle preparation method was optimized focusing the effect of 
drug-polymer interaction on drug solubilization in nanomicelle core, 
in order to achieve higher solubility of dexamethasone (>1 mg/mL). 
These results suggest that this nanomicellar formulation may be able 
to provide therapeutic levels of dexamethasone and other hydrophobic 
anti-inflammatory agents to the back of the eye subsequent 
topical administration, such as for the treatment of uveitis. Future 
improvements on this formulation are planned to study the effect of 
nanomicelle size on transport across the excised rabbit sclera aiming 
the delivery of drugs to the intermediate and posterior eye segments 
following topical administration [93].
Nanoemulsions
Nanoemulsions is an oil-in-water emulsions, in which droplets 
consisting of lipid monolayer enclosing liquid lipid core is formed. These 
structures are stabilized by the use of surfactants, which, along with the 
small size of nanoemulsions, provide increased membrane permeability, 
thus permeation is higher in the deeper layers of ocular structure and 
facilitated drug uptake. Hence, these systems offer a faster therapeutic 
action using smaller doses which means fewer ocular side effects and less 
applications per day, enhancing patient compliance [94]. Nevertheless, 
nanoemulsions are not suitable for sustained drug release [95]. The in 
situ-forming gels are polymeric solutions that undergo gelation after 
instillation in the eye because of the phase transition properties of 
polymers [96]. Thus, by incorporating a nanoemulsion into an in situ-
forming gel, an increase in the residence time of nanoemulsion in eyes, 
improving the therapeutic performance of the drug, may be achieved. 
For this purpose, an in situ poloxamer-based nanoemulsion gel of 
loteprednol etabonate, an ester-based corticosteroid used for topical 
management of several ocular inflammatory diseases, and inflammation 
after cataract surgery, was developed to upgrade the performance of this 
drug relatively to conventional eye suspensions [97]. Polymeric NPs are 
colloidal particles able to encapsulate (dissolved or dispersed) bioactive 
or drug molecules, including chemotherapeutic agents, proteins, and 
nucleic acid, for biomedical application [98]. Light-responsive NPs 
were formulated based in a far ultraviolet light-sensitive polymer 57 to 
encapsulate a small molecule angiogenesis inhibitor, nintedanib (BIBF 
1120). Furthermore, this light-responsive NPs maintained drug release 
ability and angiogenesis inhibition 10 weeks after the implantation. This 
work demonstrated a promising clinical significance of this nanosystem 
for intravitreal drug delivery [99].
Nanogels
Nanogels are also called as hydrogels made of nanoscale system with 
lipophobic polymers (e.g., nisopropylacrylamide and 2-hydroxyl 
methacrylate-lactide-dextran macromer), directly loaded with the 
drug, both hydrophilic and hydrophobic drugs. The kinetics for the 
release of administered drug from nanogels can be controlled through 
degradation rate of the cross-links and through peripheral stimuli such 
as pH and temperature [90]. Previously described nanogels were found 
to be able to bypass the ocular biological barriers, and thus to be used as 
intraocular drug delivery carriers and deliver drugs to the retina [100]. 
More recently, nanogels presenting promising properties for ocular 
drug delivery and constituting viable alternatives to conventional eye 
drops for the treatment of ocular diseases were reported [101].
Cyclodextrins (CD)
Nanosystems based on CD are capable of delivering the drugs from 
the surface of eye into its posterior segment [102]. The molecule has a 
water-soluble hydrophilic exterior, and an apolar cavity that provides a 
hydrophobic matrix capable of hosting a wide range of guest molecules, 
ranging from polar molecules to a polar molecule [103]. CD (cyclic 
oligosaccharides, CDs) have been proposed as a new attractive biomaterial 
to obtain hydrogels, combining both, the favorable property of CDs to 
form inclusion complexes and the swelling behavior of hydrogels [104]. 
The potential use of a CD-based nanosystem for enhanced stability, 
efficacy in the treatment of ocular allergic conjunctivitis, and ocular 
bioavailability of loteprednol etabonate were described recently [105]. 
In this study, the authors prepared complexes of loteprednol etabonate 
with each of hydroxylpropyl‑β‑CD and β‑CD. These complexes were 
then incorporated into different ophthalmic preparations, namely, 
gels, eye drops, and ocuserts based on hydroxypropyl methylcellulose, 
methylcellulose, and sodium alginate. It was found that higher drug 
release was obtained from the hydroxylpropyl‑β‑CD complex. Regarding 
stability, anti-inflammatory activity against allergic conjunctivitis and 
bioavailability in rabbits’ eyes, more satisfactory results were obtained 
with hydroxypropyl methylcellulose-based formulations with the 
hydroxylpropyl‑β‑CD complex. It is also important to mention that 
cyclodextrin derivatives-based therapies per se are currently a very 
promising route of intervention for ocular diseases [106].
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Dendrimers
Dendrimers are highly branched, star-like, typically water soluble, 
chemically tunable macromolecule systems with three components, 
namely, (1) a central core, (2) an exterior surface with the functional 
surface groups, and (3) an interior dendritic structure. Dendrimers are 
mainly prepared from polyamidoamine (PAMAM). The efficiency of 
PAMAM dendrimer in DNA delivery, has been shown to be improved on by 
partial PEGlation, acetylation, and alkylation [107]. Drugs are also being 
captured in dendrimer network through hydrogen bonds, interaction 
of ions, and conjugated through covalent bonds or hydrophobic 
interactions [90]. Dendrimers can able to provide a sustainable 
delivery of drug to posterior segment. Nonetheless, their cytotoxicity, 
which depends on the functional group, seems to be a limitation. 
In previous studies using the intravitreal management of PAMAM 
dendrimers in animal models of neuroinflammation, dendrimers were 
selectively localized in the activated microglia, suggesting that they are 
appropriate deliver drug systems to these cells and hence potentially 
useful in the treatment of retinal neuroinflammation for a sustained 
period [108]. PAMAM dendrimers by cationic and anionic functional 
groups are used to prepare different formulations to examine their 
effect on ocular delivery followed by topical and subconjunctival 
applications, less invasive than intravitreal route. Authors observed 
an improved concentration of the dexamethasone within the retina, 
after topical or subconjunctival application of dexamethasone-PAMAM 
complex formulations. Some of these complexes also enhanced in vitro 
permeability and in vivo ocular distribution of dexamethasone, in 
addition to ex vivo transport through both the sclera tissues and cornea 
of dexamethasone. Accordingly, these nanosystems seem to be capable 
delivery systems for dexamethasone to retina by topical application, 
since this is safest and relaxed ocular route for application [109].
Quantum dots (QDs)
QDs have a significant influence on research in many different 
fields such as chemical, physical, and biological sciences. These are 
semiconductor nanocrystals whose measurements are in the range 
of 2-6 nm [110]. The QDs consist of heavy metal core (e.g., cadmium 
selenide), with a transitional unreactive zinc sulfide shell and an outer 
coating of various bioactive molecules, aiming to definite application. 
Their composition and small size grant unique fluorescent and optical 
properties that cannot be attained with traditional fluorophores: (1) 
Higher signal-to-noise ratio and minimal photobleaching and (2) broad 
absorption spectra but actual narrow emission spectra [111]. Thus, the 
main application that is known for QDs, namely in ophthalmology, is as 
imaging agents for labeling, for instance, neurons, glia, and endothelial 
cells in retinal capillaries [112]. Another approach involving QDs that 
has been under development is the neuronal activation with optical 
stimulation of photoresponsive surfaces. Recently, it was reported that 
it has facility to transport electrical stimulus to retinal cells by silicon-
based QDs in retinal degeneration [113]. Therefore, improvements 
need to be done in drug loading, release, biodistribution, toxicity, ocular 
irritation, and patient compliance.
CONCLUSION
Concerning about the ocular diseases such as DR and DME, the 
common treatments are intravitreal anti-VEGF drugs and surgery. The 
significant number of drugs which are deliver to the posterior segment 
of the eye like intravitreal injections are needed. Nanotechnology is the 
contemporary topic because of its potential applications in many fields 
such asbiology and medicine. For the posterior segments diseases, 
nanometer-scaled particles can be used. Nanotechnology seem to 
be a promising route since they are able to bypass the blood–retinal 
barrier, reducing the treatment administration, and remains longer 
period in the eye. Nanotechnology described as a very effective therapy 
of posterior eye segment diseases like DR. In this review, the current 
strategies for the treatment of DR using nanotechnology-based system 
include nanoparticles, nanoemulsions, nanogels, CD, QDs, dendrimers, 
and nanomicelles are explained.
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